United Gets EC Marketing Ok For Unituxin In Paediatric High-Risk Neuroblastoma

(RTTNews) - United Therapeutics Corp. (UTHR) Monday said that the European Commission has granted Marketing Authorisation for Unituxin (dinutuximab) for the treatment of high-risk neuroblastoma in patients aged 12 months to 17 years.

These patients need to have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and autologous stem cell transplantation or ASCT.

Unituxin is administered in combination with granulocyte-macrophage colony-stimulating factor, interleukin-2, and isotretinoin.

Neuroblastoma is the most common extracranial solid cancer in childhood and the most common cancer in infancy, with an annual incidence in the European Union of about 1500 patients, of whom 50 percent are diagnosed as having high-risk disease.

The European approval was based on demonstration of improved event-free survival and overall survival in a multicenter, open-label, randomized trial sponsored by the US National Cancer Institute under a Cooperative Research and Development Agreement with United Therapeutics and conducted by the Children's Oncology Group.